Atypical hemolytic uremic syndrome is a life-threatening thrombotic microangiopathy due to complement dysregulation that can be triggered by systemic inflammatory states. We describe a patient with inflammatory bowel disease presenting with pain, melena, and laboratory test results showing hemolytic anemia, thrombocytopenia, and acute kidney injury. Subsequent testing led to a diagnosis of atypical hemolytic uremic syndrome, prompting initiation of eculizumab with rapid improvement in his hemolysis, thrombocytopenia, and acute kidney injury. Providers should maintain a high index of suspicion for uncommon but grave conditions associated with inflammatory bowel disease and consider complement testing if thrombotic microangiopathy is suspected.
No takes yet. Share an insight, caveat, or question.
Ryan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: